Biotechnology UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended the use of Piqray (alpelisib) for use in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2), locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy. 14 July 2022